Myocarditis: Differences in Clinical Expression between Patients with ST-Segment Elevation in Electrocardiogram vs. Patients without ST-Segment Elevation
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Population
2.2. Inclusion and Exclusion Criteria
2.3. Data Collection
2.4. Statistical Data Analysis
3. Results
3.1. Epidemiological and Clinical Differences
3.2. Laboratory Tests Comparison
3.3. Echocardiographical Differences
3.4. Heart Magnetic Resonance Imaging Differences between the Groups
3.5. Treatment Differences
3.6. Six-Month Echocardiographical Follow-Up
4. Discussion
5. Conclusions
6. Limitations
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Roth, G.A.; Mensah, G.A.; Johnson, C.O.; Addolorato, G.; Ammirati, E.; Baddour, L.M.; Barengo, N.C.; Beaton, A.Z.; Benjamin, E.J.; Benziger, C.P.; et al. Global burden of cardiovascular diseases and risk factors, 1990–2019. J. Am. Coll. Cardiol. 2020, 76, 2982–3021. [Google Scholar] [CrossRef] [PubMed]
- Ammirati, E.; Moslehi, J.J. Diagnosis and Treatment of Acute Myocarditis. JAMA 2023, 329, 1098. [Google Scholar] [CrossRef] [PubMed]
- Caforio, A.L.P.; Pankuweit, S.; Arbustini, E.; Basso, C.; Gimeno-Blanes, J.; Felix, S.B.; Fu, M.; Heliö, T.; Heymans, S.; Jahns, R.; et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2013, 34, 2636–2648. [Google Scholar] [CrossRef] [PubMed]
- Buttà, C.; Zappia, L.; Laterra, G.; Roberto, M. Diagnostic and prognostic role of electrocardiogram in acute myocarditis: A comprehensive review. Ann. Noninvasive Electrocardiol. 2019, 25, 125–134. [Google Scholar] [CrossRef] [PubMed]
- Piccirillo, F.; Watanabe, M.; Di Sciascio, G. Diagnosis, treatment and predictors of prognosis of myocarditis. A narrative review. Cardiovasc. Pathol. 2021, 54, 107362. [Google Scholar] [CrossRef] [PubMed]
- Biesbroek, P.S.; Beek, A.M.; Germans, T.; Niessen, H.W.; van Rossum, A.C. Diagnosis of myocarditis: Current state and future perspectives. Int. J. Cardiol. 2015, 191, 211–219. [Google Scholar] [CrossRef] [PubMed]
- Sharma, A.N.; Stultz, J.R.; Bellamkonda, N.; Amsterdam, E.A. Fulminant Myocarditis: Epidemiology, Pathogenesis, Diagnosis, and Management. Am. J. Cardiol. 2019, 124, 1954–1960. [Google Scholar] [CrossRef] [PubMed]
- Ammirati, E.; Cipriani, M.; Moro, C.; Raineri, C.; Pini, D.; Sormani, P.; Mantovani, R.; Varrenti, M.; Pedrotti, P.; Conca, C.; et al. Registro Lombardo delle Miocarditi. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis: Multicenter lombardy registry. Circulation 2018, 138, 1088–1099. [Google Scholar] [CrossRef] [PubMed]
- Ammirati, E.; Frigerio, M.; Adler, E.D.; Basso, C.; Birnie, D.H.; Brambatti, M.; Friedrich, M.G.; Klingel, K.; Lehtonen, J.; Moslehi, J.J.; et al. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. Circ. Heart Fail. 2020, 13, e007405. [Google Scholar] [CrossRef] [PubMed]
- Fairweather, D.; Beetler, D.J.; Musigk, N.; Heidecker, B.; Lyle, M.A.; Cooper, L.T.; Bruno, K.A. Sex and gender differences in myocarditis and dilated cardiomyopathy: An update. Front. Cardiovasc. Med. 2023, 10, 1129348. [Google Scholar] [CrossRef] [PubMed]
- Goitein, O.; Sabag, A.; Koperstein, R.; Hamdan, A.; Di Segni, E.; Konen, E.; Matetzky, S. Role of C reactive protein in evaluating the extent of myocardial inflammation in acute myocarditis. J. Cardiovasc. Magn. Reson. 2015, 17, P291. [Google Scholar] [CrossRef]
- Chapman, A.R.; Adamson, P.D.; Shah, A.S.V.; Anand, A.; Strachan, F.E.; Ferry, A.V.; Lee, K.K.; Berry, C.; Findlay, I.; Cruikshank, A.; et al. High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction. Circulation 2020, 141, 161–171. [Google Scholar] [CrossRef] [PubMed]
- Chaulin, A.M. Elevation Mechanisms and Diagnostic Consideration of Cardiac Troponins under Conditions Not Associated with Myocardial Infarction. Part 1. Life 2021, 11, 914. [Google Scholar] [CrossRef] [PubMed]
- Blauwet, L.A.; Cooper, L.T. Antimicrobial agents for myocarditis: Target the pathway, not the pathogen. Heart 2009, 96, 494–495. [Google Scholar] [CrossRef] [PubMed]
- Kociol, R.D.; Cooper, L.T.; Fang, J.C.; Moslehi, J.J.; Pang, P.S.; Sabe, M.A.; Shah, R.V.; Sims, D.B.; Thiene, G.; Vardeny, O.; et al. Recognition and Initial Management of Fulminant Myocarditis. Circulation 2020, 141, E69–E92. [Google Scholar] [CrossRef] [PubMed]
- Attia, Z.I.; Harmon, D.M.; Behr, E.R.; A Friedman, P. Application of artificial intelligence to the electrocardiogram. Eur. Heart J. 2021, 42, 4717–4730. [Google Scholar] [CrossRef] [PubMed]
STE Pattern Group (25) | Non-STE Pattern Group (13) | p Value | |
---|---|---|---|
Age (years) | 31.88 ± 6.70 | 30.23 ± 11.28 | 0.574 |
Male gender | 24 (96.00%) | 9 (69.23%) | 0.038 |
Female gender | 1 (4.00%) | 4 (30.77%) | 0.038 |
BMI (kg/m2) | 25.78 ± 3.95 | 29.05 ± 5.39 | 0.049 |
Heart rate (bpm) | 80.84 ± 13.10 | 79.00 ± 12.23 | 0.672 |
Systolic blood pressure (mmHg) | 123.16 ± 13.20 | 132.85 ± 15.87 | 0.073 |
Diastolic blood pressure (mmHg) | 76.80 ± 9.36 | 83.38 ± 7.57 | 0.026 |
In-hospital days | 7.96 ± 3.59 | 7.08 ± 2.18 | 0.353 |
Presence of infection | 21 (84.00%) | 6 (46.15%) | 0.024 |
STE Pattern Group (25) | Non-STE Pattern Group (13) | p Value | |
---|---|---|---|
Maximum Troponin I levels (mcg/mL) | 15.71 ± 26.72 | 8.08 ± 7.02 | 0.200 |
Troponin I levels at discharge (mcg/mL) | 0.32 ± 0.74 | 0.18 ± 0.31 | 0.301 |
CRP at hospitalisation (mg/L) | 103.40 ± 82.04 | 43.54 ± 61.93 | 0.017 |
CRP at discharge (mg/L) | 12.02 ± 10.82 | 7.10 ± 3.62 | 0.002 |
Haemoglobin (g/L) | 141.16 ± 14.12 | 143.15 ± 9.34 | 0.606 |
Leukocytes (×109/L) | 9.35 ± 4.01 | 8.17 ± 4.19 | 0.411 |
Neutrophils (×109/L) | 6.85 ± 3.71 | 5.45 ± 4.05 | 0.306 |
Lymphocytes (×109/L) | 1.43 ± 0.61 | 1.61 ± 0.65 | 0.416 |
Plasma creatinine concentration (mcmol/L) | 75.84 ± 18.42 | 74.69 ± 12.45 | 0.822 |
BNP (ng/L) | 75.77 ± 104.18 | 35.08 ± 38.73 | 0.144 |
Mean Concentration at the Time of Admission | Mean Concentration at the Time of Discharge | p Value | |
---|---|---|---|
Troponin I levels (mcg/L) | 12.34 ± 24.16 | 0.27 ± 0.60 | 0.010 |
CRP levels (mg/L) | 82.92 ± 80.24 | 10.34 ± 9.26 | <0.001 |
STE Pattern Group (25) | Non-STE Pattern Group (13) | p Value | |
---|---|---|---|
LVEDD | 48.82 ± 3.55 | 50.69 ± 4.05 | 0.180 |
LVEDDi | 23.66 ± 1.95 | 24.00 ± 2.56 | 0.691 |
LVMI | 88.55 ± 23.03 | 88.61 ± 19.81 | 0.994 |
LVEF | 49.71 ± 4.14 | 56.58 ± 3.99 | <0.001 |
LV strain | 16.31 ± 3.82 | 18.93 ± 3.83 | 0.228 |
Diastolic dysfunction | 7 (28.00%) | 3 (23.08%) | 1.000 |
Pericardial effusion | 4 (16.00%) | 2 (15.38%) | 1.000 |
STE Pattern Group (25) | Non-STE Pattern Group (13) | p Value | |
---|---|---|---|
LVEF | 59.95 ± 5.40 | 58.23 ± 7.61 | 0.112 |
EDV | 194.53 ± 32.42 | 185.51 ± 29.57 | 0.342 |
Indexed EDV | 94.07 ± 12.72 | 88.36 ± 10.95 | 0.682 |
ESV | 77.92 ± 17.80 | 78.29 ± 22.65 | 0.158 |
Indexed ESV | 37.84 ± 7.93 | 37.14 ± 9.14 | 0.189 |
SV | 116.21 ± 19.74 | 106.76 ± 15.62 | 0.945 |
Indexed SV | 60.05 ± 23.09 | 51.07 ± 7.56 | 0.811 |
LVMI | 77.07 ± 13.72 | 74.79 ± 10.65 | 0.087 |
Relaxation time T1 | 1339.53 ± 111.03 | 1343.69 ± 116.82 | 0.919 |
Relaxation time T2 | 42.74 ± 6.39 | 46.15 ± 7.04 | 0.165 |
Prescribed Treatment | STE Pattern Group (25) | Non-STE Pattern Group (13) |
---|---|---|
No specific treatment | 7 (28%) | 2 (15.38%) |
Antibiotics | 2 (8%) | 0 (0%) |
Optimal heart failure treatment | 1 (4%) | 7 (53.85%) |
Beta-adrenoblockers | 6 (24%) | 2 (15.38%) |
Antibiotics and optimal heart failure treatment | 9 (36%) | 2 (15.38%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ramantauskaitė, G.; Okeke, K.A.; Mizarienė, V. Myocarditis: Differences in Clinical Expression between Patients with ST-Segment Elevation in Electrocardiogram vs. Patients without ST-Segment Elevation. J. Pers. Med. 2024, 14, 1057. https://doi.org/10.3390/jpm14101057
Ramantauskaitė G, Okeke KA, Mizarienė V. Myocarditis: Differences in Clinical Expression between Patients with ST-Segment Elevation in Electrocardiogram vs. Patients without ST-Segment Elevation. Journal of Personalized Medicine. 2024; 14(10):1057. https://doi.org/10.3390/jpm14101057
Chicago/Turabian StyleRamantauskaitė, Grytė, Kingsley A. Okeke, and Vaida Mizarienė. 2024. "Myocarditis: Differences in Clinical Expression between Patients with ST-Segment Elevation in Electrocardiogram vs. Patients without ST-Segment Elevation" Journal of Personalized Medicine 14, no. 10: 1057. https://doi.org/10.3390/jpm14101057
APA StyleRamantauskaitė, G., Okeke, K. A., & Mizarienė, V. (2024). Myocarditis: Differences in Clinical Expression between Patients with ST-Segment Elevation in Electrocardiogram vs. Patients without ST-Segment Elevation. Journal of Personalized Medicine, 14(10), 1057. https://doi.org/10.3390/jpm14101057